JP2008525342A5 - - Google Patents

Download PDF

Info

Publication number
JP2008525342A5
JP2008525342A5 JP2007547323A JP2007547323A JP2008525342A5 JP 2008525342 A5 JP2008525342 A5 JP 2008525342A5 JP 2007547323 A JP2007547323 A JP 2007547323A JP 2007547323 A JP2007547323 A JP 2007547323A JP 2008525342 A5 JP2008525342 A5 JP 2008525342A5
Authority
JP
Japan
Prior art keywords
inhibitor
antibody
factor xii
protease
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007547323A
Other languages
English (en)
Japanese (ja)
Other versions
JP5118492B2 (ja
JP2008525342A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2005/013714 external-priority patent/WO2006066878A1/en
Publication of JP2008525342A publication Critical patent/JP2008525342A/ja
Publication of JP2008525342A5 publication Critical patent/JP2008525342A5/ja
Application granted granted Critical
Publication of JP5118492B2 publication Critical patent/JP5118492B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2007547323A 2004-12-23 2005-12-20 血栓の形成の防止および／または安定化の防止 Expired - Lifetime JP5118492B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04030593.0 2004-12-23
EP04030593 2004-12-23
PCT/EP2005/013714 WO2006066878A1 (en) 2004-12-23 2005-12-20 Prevention of thrombus formation and/or stabilization

Publications (3)

Publication Number Publication Date
JP2008525342A JP2008525342A (ja) 2008-07-17
JP2008525342A5 true JP2008525342A5 (cg-RX-API-DMAC7.html) 2009-02-19
JP5118492B2 JP5118492B2 (ja) 2013-01-16

Family

ID=34927953

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007547323A Expired - Lifetime JP5118492B2 (ja) 2004-12-23 2005-12-20 血栓の形成の防止および／または安定化の防止

Country Status (14)

Country Link
US (3) US8119137B2 (cg-RX-API-DMAC7.html)
EP (2) EP2272565A3 (cg-RX-API-DMAC7.html)
JP (1) JP5118492B2 (cg-RX-API-DMAC7.html)
KR (1) KR101277097B1 (cg-RX-API-DMAC7.html)
CN (1) CN101102819A (cg-RX-API-DMAC7.html)
AU (1) AU2005318464B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0519349A8 (cg-RX-API-DMAC7.html)
CA (1) CA2591786C (cg-RX-API-DMAC7.html)
DK (1) DK1830924T3 (cg-RX-API-DMAC7.html)
ES (1) ES2407965T3 (cg-RX-API-DMAC7.html)
MX (1) MX2007006997A (cg-RX-API-DMAC7.html)
PL (1) PL1830924T3 (cg-RX-API-DMAC7.html)
RU (1) RU2514878C2 (cg-RX-API-DMAC7.html)
WO (1) WO2006066878A1 (cg-RX-API-DMAC7.html)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
PT2298278E (pt) 2002-06-07 2016-02-25 Dyax Corp Prevenção e redução da perda de sangue e resposta inflamatória
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
WO2004019968A1 (en) 2002-08-28 2004-03-11 Dyax Corp. Methods for preserving organs and tissues
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
GB0607515D0 (en) * 2006-04-13 2006-05-24 Axis Shield Diagnostics Ltd Anti-factor xlla therapy
EP2051707B1 (en) 2006-07-31 2013-07-17 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
DK2109457T3 (en) 2007-02-12 2016-04-11 Csl Behring Gmbh THERAPEUTIC USE OF KAZAL TYPE SERINE PROTEASE INHIBITORS
WO2009026539A1 (en) * 2007-08-23 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
EP2215256A1 (en) * 2007-10-22 2010-08-11 Georg Dewald Disorders of vasoregulation and methods of diagnosing them
EP2103311A1 (en) 2008-03-20 2009-09-23 CSL Behring GmbH The calcium sensor STIM1 is essential for pathological thrombus formation
EP2145900A1 (en) 2008-07-15 2010-01-20 CSL Behring GmbH Orai1 (CRACM1) is the platelet SOC channel and essential for pathological thrombus formation
JP2013516389A (ja) 2009-01-06 2013-05-13 ダイアックス コーポレーション カリクレイン阻害剤による粘膜炎治療
EP2269597A1 (en) 2009-06-22 2011-01-05 CSL Behring GmbH CLEC-2 is an essential platelet activating receptor in hemostasis and thrombosis
EP2272874A1 (en) 2009-07-10 2011-01-12 CSL Behring GmbH Role of PLD1 in thrombus formation and integrin alpha IIb beta 3 activation
ES2905545T3 (es) 2010-01-06 2022-04-11 Takeda Pharmaceuticals Co Proteínas de unión a calicreína plasmática
EP2371857A1 (en) * 2010-04-01 2011-10-05 CSL Behring GmbH Factor XII inhibitors for treating interstitial lung disease
WO2012064758A2 (en) * 2010-11-08 2012-05-18 Isis Pharmaceuticals, Inc. Methods for modulating factor 12 expression
KR102011156B1 (ko) 2011-01-06 2019-08-16 다이액스 코포레이션 혈장 칼리크레인 결합 단백질
CN103415301A (zh) * 2011-03-09 2013-11-27 德国杰特贝林生物制品有限公司 用于与包括与人造表面接触的医疗操作一起施用的fxii抑制剂
EP2497489A1 (en) * 2011-03-09 2012-09-12 CSL Behring GmbH Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
US9187749B2 (en) 2011-06-10 2015-11-17 Isis Pharmaceuticals, Inc. Methods for modulating factor 12 expression
HRP20250164T1 (hr) 2011-07-22 2025-04-11 Csl Behring Gmbh Inhibitorna monoklonska antitijela protiv faktora xii/xiia i njihove uporabe
EP2548892A1 (en) 2011-07-22 2013-01-23 CSL Behring GmbH Inhibitory anti-Factor XII/XIIa monoclonal Antibodies and their uses
US20140296146A1 (en) * 2011-08-23 2014-10-02 Synapse B.V. Thermostable Inhibitors of Activation of the Blood Clotting System Through Contact with Foreign Surfaces
EP2623110A1 (en) * 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
WO2014089493A1 (en) * 2012-12-07 2014-06-12 Vanderbilt University Antibodies against factor xii and uses thereof
WO2014135694A1 (en) 2013-03-08 2014-09-12 Csl Behring Ag Treatment and prevention of remote ischemia-reperfusion injury
CA2916399C (en) * 2013-06-28 2022-08-02 Marc Nolte Combination therapy using a factor xii inhibitor and a c1-inhibitor
DK3157548T3 (da) * 2014-06-18 2021-09-06 Csl Behring Gmbh Terapi anvendelse af en faktor xii-inhibitor i en neurotraumatisk sygdom
CA2972800A1 (en) 2015-01-02 2016-07-07 Dyax Corp. Bispecific antibodies against plasma kallikrein and factor xii
JP2018521960A (ja) * 2015-04-28 2018-08-09 エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ（ウペエフエル）Ｅｃｏｌｅ Ｐｏｌｙｔｅｃｈｎｉｑｕｅ Ｆｅｄｅｒａｌｅ ｄｅ Ｌａｕｓａｎｎｅ （ＥＰＦＬ） 酵素で活性化された第ＸＩＩ因子（ＦＸＩＩａ）の新規阻害剤
EP3325516B1 (en) 2015-07-21 2021-12-15 Takeda Pharmaceutical Company Limited A monoclonal antibody inhibitor of factor xiia
US11286307B2 (en) 2015-12-11 2022-03-29 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
EP3440107A4 (en) * 2016-04-06 2020-02-19 CSL Limited METHOD FOR TREATING ATHEROSCLEROSIS
WO2019113642A1 (en) 2017-12-15 2019-06-20 Csl Limited Use of a fxiia-inhibitor in the treatment of renal fibrosis and/or chronic kidney disease
EA202190056A1 (ru) * 2018-06-19 2021-05-28 Ридженерон Фармасьютикалз, Инк. АНТИТЕЛА ПРОТИВ ФАКТОРА XII/XIIa И ИХ ПРИМЕНЕНИЕ
US12134657B2 (en) 2018-11-28 2024-11-05 Oregon Health & Science University Therapeutic factor XII antibody
WO2021007190A1 (en) 2019-07-08 2021-01-14 Rezolute, Inc. Processes for preparing plasma kallikrein inhibitors
AU2021209045A1 (en) 2020-01-13 2022-07-28 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
US20240352150A2 (en) * 2020-06-16 2024-10-24 Ningbo Comgen Biotech Co., Ltd. Anti-factor xii (fxii) nanobody or antigen-binding fragment thereof, and use thereof
AR124408A1 (es) 2020-12-18 2023-03-22 Ionis Pharmaceuticals Inc Compuestos y métodos para modular el factor xii
KR20260042526A (ko) 2023-07-19 2026-03-31 리제너론 파아마슈티컬스, 인크. 항-인자 XII/XIIa 항체 및 이의 용도
TWI918151B (zh) 2024-09-25 2026-03-11 吳文良 毛豆胜肽在抗血栓形成上的用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK225488D0 (da) * 1988-04-26 1988-04-26 Novo Industri As Polypeptid
US4963657A (en) * 1988-06-09 1990-10-16 Temple University Of The Commonwealth System Of Higher Education Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same
WO1994020535A1 (en) * 1992-12-11 1994-09-15 Corvas International, Inc. ECOTIN AS A FACTOR Xa, XIa, AND XIIa INHIBITOR
CA2170030A1 (en) 1993-09-14 1995-03-23 Robert A. Lazarus Pharmaceutical compositions containing ecotin and homologs thereof
ZA963619B (en) 1995-05-08 1996-11-22 Scios Inc Protease inhibitor peptides
US20030109680A1 (en) * 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
DE19725014A1 (de) * 1997-06-13 1998-12-17 Bayer Ag Aprotininvarianten mit verbesserten Eigenschaften und Bikunine von Aprotininvarianten
GB9800817D0 (en) 1998-01-16 1998-03-11 Bio Discovery Ltd Serine protease inhibitors
JP2002517739A (ja) * 1998-06-08 2002-06-18 ユニバーシティ オブ バーモント アンド ステイト アグリカルチャー カレッジ 血液および血液製剤における凝固の抑制
CA2345641A1 (en) * 1998-09-28 2000-04-06 Merck & Co., Inc. A method for treating inflammatory diseases by administering a thrombin inhibitor
DK1222929T3 (da) * 2001-01-11 2010-09-06 Life Sciences Res Partners Vzw Fremgangsmåde og farmaceutisk sammensætning til forebyggelse og/eller behandling af systematisk betændelsesreaktionssyndrom
PT2298278E (pt) * 2002-06-07 2016-02-25 Dyax Corp Prevenção e redução da perda de sangue e resposta inflamatória
US7153829B2 (en) * 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
WO2004004640A2 (en) 2002-07-05 2004-01-15 Tetragrammaton Inc. Methods, compositions and kits for treating damage to excitable tissue
WO2004019968A1 (en) * 2002-08-28 2004-03-11 Dyax Corp. Methods for preserving organs and tissues
US20040229778A1 (en) * 2003-05-13 2004-11-18 Elmaleh David R. Pharmaceutical compositions of antithrombin III for the treatment of retroviral diseases
WO2004110356A2 (en) 2003-05-15 2004-12-23 Cbr Institute For Biomedical Research, Inc. Methods for modulating cell-to-cell adhesion using an agonist of c1inh-type protein activity
US7544853B2 (en) 2003-05-16 2009-06-09 Pharming Intellectual Property B.V. C1 inhibitor with short half-life transient treatment
EP1673134A4 (en) * 2003-09-12 2007-03-21 Marinepolymer Tech Inc RECEIVING VASCULAR ACCESS IN HEMODIALYSIS PATIENTS
GB0411145D0 (en) 2004-05-19 2004-06-23 Imp College Innovations Ltd Protease inhibitors and their therapeutic applications
US8569277B2 (en) * 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition
GB0418877D0 (en) 2004-08-24 2004-09-29 Univ Edinburgh Heart
US20060104944A1 (en) * 2004-11-18 2006-05-18 Mousa Shaker A Activators and inhibitors of protease activated receptor2 (PAR2) and methods of use
SI1669074T1 (sl) 2004-12-01 2010-10-29 Par Pharmaceuticals Inc Uporaba megestrol acetata za izboljšanje delovanja srca in zdravljenje srčnega popuščanja

Similar Documents

Publication Publication Date Title
RU2007123797A (ru) Предотвращение формирования и/или стабилизации тромбов
Kenniston et al. Inhibition of plasma kallikrein by a highly specific active site blocking antibody
Colman Are hemostasis and thrombosis two sides of the same coin?
Weitz Factor XI and factor XII as targets for new anticoagulants
Mahdy et al. Perioperative systemic haemostatic agents
Gils et al. Plasminogen activator inhibitor-1
Bryant et al. Human plasma kallikrein-kinin system: physiological and biochemical parameters
Viles-Gonzalez et al. Links between inflammation and thrombogenicity in atherosclerosis
van Montfoort et al. Recent insights into the role of the contact pathway in thrombo-inflammatory disorders
Huber-Lang et al. Auxiliary activation of the complement system and its importance for the pathophysiology of clinical conditions
Burster et al. Hindrance of the proteolytic activity of neutrophil-derived serine proteases by serine protease inhibitors as a management of cardiovascular diseases and chronic inflammation
NO20091647L (no) Trypsinlignende serinproteaseinhibitorer og deres fremstilling og anvendelse
WO1996035788A3 (en) Kunitz type protease inhibitors
Demoulin et al. Dual inhibition of factor XIIa and factor XIa as a therapeutic approach for safe thromboprotection
Vercauteren et al. Thrombin activatable fibrinolysis inhibitor: a putative target to enhance fibrinolysis
ES2542335T3 (es) Tratamiento de trastornos tromboembólicos con rivaroxabán
WO1994020526A1 (en) Peptide boronic acid derivatives having protease inhibiting activity
Brito et al. The Kallikrein Inhibitor from Bauhinia bauhinioides (BbKI) shows antithrombotic properties in venous and arterial thrombosis models
Jagneaux et al. Coagulation in sepsis
Mukaiyama et al. Abdominal aortic aneurysm complicated with chronic disseminated intravascular coagulopathy: a case of surgical treatment
JP6319592B2 (ja) 静脈血栓状態の予防および治療のための、ブロメラインとナットウキナーゼとを含む線維素溶解組成物
Mammen Perspectives for the future
WO1999063090A3 (en) Protease inhibitor peptides
Blat et al. A renaissance for the contact system in blood coagulation?
Lupu et al. Plasmin‐dependent proteolysis of tissue factor pathway inhibitor in a mouse model of endotoxemia